12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arenegyr: Phase II started

MolMed began an open-label, Italian Phase II trial (Study NGR005) of 0.8 or 45 µg/m 2 of IV Arenegyr every...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >